恩瑞格适应症

Indications: It is used for patients with iron accumulation due to long-term blood transfusion (such as thalassemia or other rare anemias). It is suitable for children over two years old and adults.

The chemical name of Deferasirox (Enrige) is 4-[3,5-bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]benzoic acid. It is an iron chelator product developed by the Swiss pharmaceutical company Novartis. It is the first oral iron-removing agent approved by the US FDA for routine use. It is approved for use in patients ≥2 years old with chronic iron overload caused by blood transfusion. In Europe, it is recommended as a 6 First-line drug for patients with thalassemia and iron overload over 10 years of age.

Thalassemia, also known as thalassemia, is a group of genetic diseases. The pathogenesis is that the globin chain that synthesizes hemoglobin is reduced or missing, resulting in abnormal hemoglobin structure. The red blood cells containing abnormal hemoglobin have reduced deformability and shortened lifespan. They can be destroyed by the liver and spleen of the human body in advance, leading to anemia and even developmental abnormalities. This disease is also known as hemolytic anemia in medical terms. The incidence of thalassemia is higher, especially in certain regions of our country. Thalassemia is more harmful and patients require long-term blood transfusions to maintain their life and health.

Symptoms of thalassemia: 1. Severe anemia, progressive hepatosplenomegaly, jaundice, and dysplasia occur within a few days of birth. The special symptoms include: large head, widened eye distance, saddle nose, protruding forehead, and protruding cheeks. The typical manifestation is a buttock-shaped head, and long bones can be fractured. The skeletal changes are caused by excessive hematopoietic function of the bone marrow, widening of the bone marrow cavity, and thinning of the cortex. A few patients develop chest masses between the ribs and spine, and cholelithiasis and lower limb ulcers may also be seen. 2. Intermediate type: mild to moderate anemia, most patients can survive to adulthood. 3. Mild anemia or asymptomatic, usually found during family history investigation.

The treatment of thalassemia has good safety and tolerance, can significantly reduce the iron load on the heart and liver, and is easily accepted by patients.